Douglas DiRuggiero, DMSc, MHS, PA-C, shares how oral and targeted therapies in psoriasis are discussed at Horizons in Advanced Practice and what he expects across inflammatory skin disease in 2027.

This interview covers why unbranded, peer-driven sessions help advanced practice clinicians at every experience level compare treatment options, choose among them, and decide which patients qualify. DiRuggiero describes how attendees exchange approaches to presenting data and options to patients, and how to request the data they need from medical science liaisons and representatives for use in the exam room.

He also previews his presentation with Lakshi Aldredge on oral and targeted therapies in psoriasis, including continued biologic studies, joint indications, and newly available oral peptides. His goal is greater clinician confidence in managing patients and guiding shared decision-making based on comorbidities and prior therapy failures.

Looking toward 2027, DiRuggiero discusses icotrokinra, new TYK2 inhibitors, combination medicines in the monoclonal antibody space, new hidradenitis suppurativa guidelines, and expanding targeted therapy research across atopic dermatitis, HS, and psoriasis. Viewers hear which advances he is watching most closely, from possible data in younger age groups to joint outcomes, and how a newly identified pathway can lead to a therapeutic designed to interrupt it.
————-

0:00 – Introduction
0:30 – Value of Unbranded Horizons Sessions
1:17 – Oral and Targeted Psoriasis Therapies
1:58 – Pipeline Outlook for 2027
—————

🔗 Read more: https://www.dermatologytimes.com/view/shared-decision-making-with-oral-and-targeted-psoriasis-therapies
📩 Subscribe for more: https://www.youtube.com/@DermatologyTimes
🌐 Visit us: https://www.dermatologytimes.com/
—————-

Dermatology Times is the leading multimedia resource for dermatologists and clinicians who treat skin conditions. Visit us at dermatologytimes.com for the latest clin